Universitätsklinik für Augenheilkunde, University of Bern, Switzerland.
Acta Ophthalmol. 2013 Sep;91(6):526-30. doi: 10.1111/j.1755-3768.2012.02457.x. Epub 2012 Jun 14.
To evaluate 3-year follow-up treatment outcomes with ranibizumab (Lucentis(®)) 0.5 mg administered either monthly or quarterly on a pro re nata (PRN) basis according to a disease activity-guided monitoring and treatment algorithm.
A total of 316 treatment-naive eyes of 316 patients with exudative age-related macular degeneration met the criteria for inclusion in this retrospective, interventional case series. Patients were treated with ranibizumab 0.5 mg according to a disease activity-guided algorithm with monthly monitoring. Optical coherence tomography and fluorescein angiography were routinely used to assess disease activity: active lesions were treated with a series of three monthly injections, whereas inactive lesions were treated with quarterly injections.
Mean Early Treatment Diabetic Retinopathy Study best-corrected visual acuity improved from 52 letters at baseline to 59 letters at 12 months, achieved with a mean of 7.1 injections, 61 letters at 24 months with a mean of 5.0 injections administered in the second year and 60 letters at 36 months with a mean number of 5.2 injections.
Monthly visits and a morphology-driven PRN regimen with 3 injections in case of recurrence plus quarterly injections in case of inactive CNV resulted in an average VA gain of 7-9 letters that could be maintained over 3 years.
评估雷珠单抗（Lucentis®）0.5mg 根据疾病活动指导的监测和治疗算法，每月或每季度按需（PRN）给药的 3 年随访治疗结果。
共有 316 名渗出性年龄相关性黄斑变性患者的 316 只治疗初治眼符合本回顾性、干预性病例系列研究的纳入标准。根据疾病活动指导算法，每月监测，用雷珠单抗 0.5mg 治疗。常规使用光学相干断层扫描和荧光素血管造影评估疾病活动：活动病变用一系列 3 次每月注射治疗，而不活动病变用每季度注射治疗。
平均早期治疗糖尿病视网膜病变研究最佳矫正视力从基线时的 52 个字母提高到 12 个月时的 59 个字母，平均注射 7.1 次，24 个月时为 61 个字母，第二年平均注射 5.0 次，36 个月时为 60 个字母，平均注射 5.2 次。
每月就诊和形态驱动的 PRN 方案，在复发时用 3 次注射，在不活动的 CNV 时用每季度注射，平均可获得 7-9 个字母的 VA 增益，并可维持 3 年。
